Results 41 to 50 of about 1,204,710 (358)

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. [PDF]

, 2018
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with ...
Bairey, Osnat, Barr, Paul M., Bartlett, Nancy L., Burger, Jan A., Coutre, Steven E, Devereux, Stephen, Ghia, Paolo, Grosicki, Sebastian, Hillmen, Peter, James, Danelle, Kipps, Thomas J, Li, Jianyong, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Styles, Lori, Tedeschi, Alessandra, Universitat Autònoma de Barcelona, Zhou, Cathy   +21 more
core   +5 more sources

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. [PDF]

, 2016
BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide ...
Balana, C., Baumert, B.G., Brandes, A.A., Bravo-Marques, J., Bromberg, J.E., Capper, D., Chinot, O., Clement, P.M., Dhermain, F., Dif, N., Enting, R., Feuvret, L., Gijtenbeek, J.M., Gorlia, T., Hartmann, C., Hassel, M.B., Hegi, M.E., Hoang-Xuan, K., Kantor, G., Kros, J.M., Kurscheid, S., Lacombe, D., Marosi, C., Mason, W.P., Nordal, R.A., Rees, J., Reijneveld, J.C., Reni, M., Rossiter, J.P., Ryan, G., Stupp, R., Taphoorn, M.J., Thiessen, B., Tzuk-Shina, T., van den Bent, M.J., von Deimling, A., Wick, W.   +36 more
core   +6 more sources

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

Acta Oncologica
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen   +10 more
doaj   +1 more source

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

The Application of Clinical Genetics, 2022
Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS, Soliman SE, Elhamouly MS, Gohar SF, Elgamal A, Alabassy MM, Soliman HA, Gadallah AA, Elbahr OD, Soliman G, Saleh AA   +10 more
doaj  

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BMC Cancer, 2021
Background An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms.
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen   +5 more
doaj   +1 more source

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]

, 2019
BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A, Dréno, Brigitte, Flaherty, Keith T, Hauschild, Axel, Larkin, James, Lewis, Karl D, McArthur, Grant A, McKenna, Edward, Mun, Yong, Ribas, Antoni, Wongchenko, Matthew, Yan, Yibing, Zhu, Qian   +12 more
core   +2 more sources

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source

The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

BMC Cancer
Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies.
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria   +13 more
doaj   +1 more source

Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer – a review of the literature from a developing country perspective

Contemporary Oncology, 2016
We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski, Violetta Sulżyc-Bielicka   +1 more
doaj   +1 more source

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer

Frontiers in Nutrition, 2023
BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie, Hailun Xie, Lishuang Wei, Shunhui Gao, Shunhui Gao, Mingxiang Liu, Mingxiang Liu, Yanren Liang, Yanren Liang, Guanghui Yuan, Guanghui Yuan, Qiwen Wang, Qiwen Wang, Yansong Xu, Shuangyi Tang, Jialiang Gan, Jialiang Gan   +16 more
doaj   +1 more source